Department of Cardiovascular Surgery, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, China; Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430077, China.
Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430077, China; Department of Laboratory Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430077, China.
Transl Res. 2024 Dec;274:49-66. doi: 10.1016/j.trsl.2024.09.003. Epub 2024 Sep 26.
Excessive subendothelial retention of oxidized low-density lipoprotein (oxLDL) and subsequent oxLDL engulfment by macrophages leads to the formation of foam cells and the development of atherosclerosis. Our previous study showed that the plasma level of sialic acid-binding immunoglobulin-like lectin 5 (Siglec-5) was a novel biomarker for the prognosis of atherosclerosis in diabetic patients. However, the role and underlying mechanisms of Siglec-5 in atherosclerosis have not been elucidated.
The interaction between oxLDL and Siglec-5 was detected by fluorescence colocalization and coimmunoprecipitation. The effect of oxLDL on Siglec-5 expression was detected in endothelial cells and macrophages, and the effect of Siglec-5 on oxLDL transcytosis and uptake was investigated. Siglec-5 was overexpressed in mice using recombinant adeno-associated virus vector serotype 9 (rAAV9-Siglec-5) to evaluate the effect of Siglec-5 on oxLDL uptake and atherogenesis in vivo. In addition, the effects of Siglec-5 antibodies and soluble Siglec-5 proteins on oxLDL transcytosis and uptake and their role in atherogenesis were investigated in vivo and in vitro.
We found that oxLDL interacted with Siglec-5 and that oxLDL stimulated the expression of Siglec-5. Siglec-5 promotes the transcytosis and uptake of oxLDL, while both anti-Siglec-5 antibodies and soluble Siglec-5 protein attenuated oxLDL transcytosis and uptake. Interestingly, overexpression of Siglec-5 by recombinant adeno-associated viral vector serotype 9 (rAAV9-Siglec-5) promoted the retention of oxLDL in the aorta of C57BL/6 mice. Moreover, overexpression of Siglec-5 significantly accelerated the formation of atherosclerotic lesions in Apoe mice. Moreover, both anti-Siglec-5 antibodies and soluble Siglec-5 protein significantly alleviated the retention of oxLDL in the aorta of rAAV9-Siglec-5-transfected C57BL/6 mice and the formation of atherosclerotic plaques in rAAV9-Siglec-5-transfected Apoe mice.
Our results suggested that Siglec-5 was a novel receptor that mediated oxLDL transcytosis and promoted the formation of foam cells. Interventions that inhibit the interaction between oxLDL and Siglec-5, including anti-Siglec-5 antibody or soluble Siglec-5 protein treatment, may provide novel therapeutic strategies in treating atherosclerosis.
氧化型低密度脂蛋白(oxLDL)过度亚内皮蓄积,随后被巨噬细胞吞噬,导致泡沫细胞形成和动脉粥样硬化的发生。我们之前的研究表明,唾液酸结合免疫球蛋白样凝集素 5(Siglec-5)的血浆水平是糖尿病患者动脉粥样硬化预后的新型生物标志物。然而,Siglec-5 在动脉粥样硬化中的作用及其潜在机制尚未阐明。
通过荧光共定位和共免疫沉淀检测 oxLDL 与 Siglec-5 的相互作用。检测 oxLDL 对内皮细胞和巨噬细胞中 Siglec-5 表达的影响,以及 Siglec-5 对 oxLDL 转胞吞和摄取的影响。利用重组腺相关病毒 9 型载体(rAAV9-Siglec-5)过表达小鼠 Siglec-5,评估 Siglec-5 对体内 oxLDL 摄取和动脉粥样硬化形成的影响。此外,还在体内和体外研究了 Siglec-5 抗体和可溶性 Siglec-5 蛋白对 oxLDL 转胞吞和摄取的影响及其在动脉粥样硬化形成中的作用。
我们发现 oxLDL 与 Siglec-5 相互作用,oxLDL 刺激 Siglec-5 的表达。Siglec-5 促进 oxLDL 的转胞吞和摄取,而抗 Siglec-5 抗体和可溶性 Siglec-5 蛋白均减弱 oxLDL 的转胞吞和摄取。有趣的是,重组腺相关病毒 9 型载体(rAAV9-Siglec-5)过表达 Siglec-5 促进了 oxLDL 在 C57BL/6 小鼠主动脉中的保留。此外,Siglec-5 的过表达显著加速了 Apoe 小鼠动脉粥样硬化病变的形成。此外,抗 Siglec-5 抗体和可溶性 Siglec-5 蛋白均显著减轻 rAAV9-Siglec-5 转染 C57BL/6 小鼠主动脉中 oxLDL 的保留和 rAAV9-Siglec-5 转染 Apoe 小鼠中动脉粥样硬化斑块的形成。
我们的结果表明 Siglec-5 是一种新型受体,介导 oxLDL 的转胞吞作用,并促进泡沫细胞的形成。抑制 oxLDL 与 Siglec-5 相互作用的干预措施,包括抗 Siglec-5 抗体或可溶性 Siglec-5 蛋白治疗,可能为治疗动脉粥样硬化提供新的治疗策略。